DCprime is collaborating with clinical centers, academic groups and other companies to drive forward the development of DCOne® based therapies. Disruptive solutions for hard-to-treat cancers can only be made possible by combining knowledge, expertise and therapeutic modalities. Therefore, our focus for collaboration is towards researchers, institutes, biotech companies and others with synergistic expertise and technologies, for example in the field of cancer vaccination, immune modulators or antigen delivery. DCprime also seeks to establish collaborations to deepen the understanding of the interaction between tumours and immune system.